Based on our findings, we hypothesize that targeting Tregs, for example, with an anti-CTLA-4 checkpoint inhibitor in biopsy-proven high-risk PanIN could be a useful therapeutic intervention to restore immune surveillance and eventually reverse the condition or prevent progression to invasive cancer (Scheme 1) [21,54,55]. Here, CTLA4 is linked to cancer.